EISAI INDIA AND MYLAN ENTER INTO CO-EXCLUSIVE MARKETING AGREEMENTTO COMMERCILIZE TECERIS® THE SECOND ERIBULIN BRAND IN INDIA
- TECERIS® aimed at expanding access to metastatic breast cancer patients in India
[Vishakhapatnam,
Bengaluru - India, September,
2019 /] -- Eisai Pharmaceuticals India Pvt. Ltd (a subsidiary company of Eisai
Co., Ltd., Headquarters: Tokyo, CEO: Haruo Naito, “Eisai India”) and Mylan
Pharmaceuticals Pvt Ltd. (Mylan), today jointly announced that they have
entered into a marketing license agreement to commercialize TECERIS®, the
Innovator’s second brand of the anticancer agent Eribulin mesylate (eribulin)
in India. TECERIS® will be manufactured and supplied by Eisai India
and marketed by Mylan. This agreement is an important strategy for expanding
the access of eribulin for the treatment of metastatic breast cancer (MBC)
patients in India.
Eribulin, a novel anticancer agent,
discovered in-house by Eisai was approved in India in April 2013 for the
treatment of locally advanced or metastatic breast cancer which previously was
being treated with at least two chemotherapy regimens including an
anthracycline and a taxane. In October 2013, Eisai India launched the eribulin
brand Halaven®for
eligible patients under its patient assistance programme.
Commenting on the co-exclusive,
marketing relationship, Dr.Sanjit Singh Lamba, Managing Director, Eisai India
said, “Our endeavor
at Eisai group always has been to ensure that we make our innovative products
more accessible to patients who have an unmet medical need. We have been doing
it through our tiered pricing programs and now we have entered into a
partnership with Mylan to address unmet medical needs. This step is a part of
our hhc philosophy of human health care thereby keeping the patient at the
center and ensuring our medicines are accessible and affordable.”
Commenting on the partnership, Mr. Rakesh Bamzai, President,
India and Emerging Markets, Mylan said, “The
launch of the innovator’s second brand of Eribulin, TECERIS® will enable
enhanced access to the medicine through our co-exclusive marketing relationship
as both Eisai India and Mylan share a commitment to bring affordable and
high-quality medicines to market, especially in areas of unmet need. Eribulin
is an important addition to our growing oncology portfolio and, expands the
available treatment options for women with advanced or metastatic stages of
breast cancer. The collaboration with Eisai India is yet another positive step
in our ongoing efforts to help improve affordability and access to essential
oncology treatments in India and serve the patient community.”
The number of women diagnosed with
breast cancer in India has increased in the recent years, with an estimated 163,000
new cases of breast cancer and approximately 87,000 related deaths in 2018.1
Breast cancer is now the most frequently diagnosed cancer in Indian women.1
Eisai group positions oncology as a
key therapeutic area and is aiming to discover revolutionary new medicines with
the potential to cure cancer. In addition, Eisai group will continue to adopt
proactive measures aimed at increasing access to its innovative pharmaceutical
products in emerging countries and the developing world in order to contribute
to an increase in the benefits provided to local patients and their families.
The
partnership between Eisai India and Mylan will lead to enhanced access and
affordability of cancer treatment for breast cancer patients in India. Mylan’s oncology portfolio in India
includes high quality, affordable cancer-related cytotoxic and targeted
therapies for breast, lung and colorectal cancer. š¢š¢
.jpg)
